Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies

Identifying effective immunotherapies for solid tumors remains challenging despite the significant clinical responses observed in subsets of patients treated with immune checkpoint inhibitors. Interleukin-15 (IL-15) is a promising cytokine for the treatment of cancer as it stimulates NK and CD8(+) l...

Descripción completa

Detalles Bibliográficos
Autores principales: Lui, Grace, Minnar, Christine M., Soon-Shiong, Patrick, Schlom, Jeffrey, Gameiro, Sofia R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297013/
https://www.ncbi.nlm.nih.gov/pubmed/37371081
http://dx.doi.org/10.3390/cells12121611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297013/
https://www.ncbi.nlm.nih.gov/pubmed/37371081
http://dx.doi.org/10.3390/cells12121611

Ejemplares similares